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Summary
Small retrospective studies have shown the
benefit of endovascular treatment with intrasinus thrombolysis (IST) or mechanical thrombectomy (MT) with/without IST (MT+/–IST) in
cases of multifocal cerebral venous thrombosis
(CVT).
Our study compares the mortality, functional
outcome and periprocedural complications
among patients treated with MT +/– IST versus
IST alone.
We reviewed clinical and angiographic findings of 63 patients with CVT who received endovascular treatment at three tertiary care centers. Primary outcome variables were discharge
mortality and neurological dysfunction, and intermediate (three months) and long-term (>six
months) morbidity. The modified Rankin scale
(mRS) was used to assess morbidity. mRS ≤1
was considered a good recovery. Neurological
dysfunction was rated as neuroscore: 0, normal;
1, mild (ambulatory, communicative); 2, moderate (non-ambulatory, communicative); and 3,
severe (non-ambulatory, non-communicative/
comatose).
In patients who received IST alone, presenting
neurological deficits were comparatively minor
(p<0.001). When the two groups were adjusted
for admission neuroscore, there was no statisti336

cal significance between discharge mortality
[7(21%) versus 4(14%), p=0.228], neurological
dysfunction (p=0.442), intermediate (p=0.336)
and long-term morbidity (p=0.988). Patients
who received MT +/- IST had a higher percentage of periprocedural complications without
reaching statistical significance.
Compared to IST, MT was performed in severe cases with extensive sinus involvement.
When adjusted for admission neurological dysfunction, both groups had similar mortality and
discharge neurological dysfunction and similar
intermediate and long-term morbidity.
Introduction
Cerebral venous thrombosis (CVT) is a rare
type of stroke (0.5-1% of all strokes) 1. It can be
a devastating disease with mortality ranging
between 4.3 and 6.8% in assessment of two
large databases 2,3. There has been a decline in
mortality in recent years due to early recognition and treatment with anticoagulation 3. There
is modest evidence from three small randomized controlled clinical trials and multiple
observational studies supporting a role for anticoagulation in the treatment of CVT regardless
of the presence of intracerebral hemorrhage
(ICH) before the initiation of treatment 1,4. De-
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spite adequate anticoagulation, patients can
still have a poor clinical outcome especially in
cases with large and extensive, rapidly progressing or multifocal thrombosis 1,4. For such
cases, endovascular delivery of fibrinolytic
agents with or without mechanical disruption
has been successfully used in multiple case reports and smaller case series 1, 5-8. The theoretical advantages of this treatment include direct
delivery of fibrinolytic agent into the clot minimizing systemic side-effects 6.
AngioJet, a rheolytic thrombectomy system
(MEDRAD, Inc, Warrendale, PA, USA) is the
most commonly used device for mechanical
thrombectomy (MT) 6,9-22, followed by the Penumbra thromboaspiration system (Penumbra,
Inc, Alameda, CA, USA) 23-27 and the MERCI

(Mechanical Embolus Removal in Cerebral
Ischemia) clot retrieval device (Concentric
Medical, Mountain View, CA, USA) 28. Mechanical methods result in more rapid recanalization and increase the surface of the thrombus
exposed to thrombolytics 6.
There is only one non-randomized comparison between anticoagulation versus IST and its
findings suggested that local thrombolysis may
be more effective than systemic heparin in selected cases 29. This study did not employ mechanical methods. A prospective series on 20
patients with severe CVT who mostly received
MT with or without IST (MT +/– IST) showed
higher mortality and post treatment ICH and
advised caution in using endovascular methods
6. We performed this study to compare the mor-

Table 1 Comparison of demographic and clinical characteristics of patients who received MT+/-IST versus IST alone.

Variables

Mechanical thrombectomy Intrasinus
thrombolysis
with/without continuous
(N=29)
thrombolytic infusion
(N=34)

P value

Age (Median, range)

35 (12-57)

32 (4-61)

0.978

Female (%)

26 (77)

20 (69)

0.576

Presenting symptoms
–	Headaches (%)
–	Seizures (%)
		SE (%)
– FND (%)
– Encephalopathy/coma (%)

34 (100)
17 (50)
4 (11)
28 (82)
21 (62)

26 (90)
10 (35)
0 (0)
18 (62)
9 (31)

0.092
0.307
0.118
0.091
0.023*

Prothrombotic conditions (%)

15 (44)

17 (59)

0.315

Venous infarction (%)
–	Non-hemorrhagic (%)
–	Hemorrhagic (%)

25 (74)
8 (24)
19 (56)

13 (45)
4 (14)
10 (35)

0.038*
0.358
0.129

25 (74)

10 (35)

24/33 (72)

6/10 (60)

25 (74)

9 (31)

4 (11)

14 (46)

Reason for procedure
– Extensive involvement of sinuses with
altered mental status/coma (%)
– Deterioration of symptoms despite being
on anticoagulation (%)
–	Large space-occupying lesions, such as
edema or (hemorrhagic) infarcts (%)
– †Other/Unspecified (%)

0.001*

Admission neurological deficit
–	Normal (%)
–	Mild (%)
–	Moderate (%)
–	Severe (%)

0 (0)
6 (17)
4 (12)
24 (71)

5 (17)
11 (38)
7 (24)
6 (21)

SD= Standard deviation; SE= Status epilepticus; FND= Focal neurological deficits
* Statistically significant
† All cases in the ‘Other’ category had persistent progressive headache or worsening papilloedema.
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tality and morbidity, angiographic recanalization and periprocedural complications between
patients who received MT +/– IST versus IST
alone.
Methods
We identified 63 patients with CVT who received endovascular treatment at three large
tertiary care centers. (University of Texas
Southwestern Medical Center, Dallas, Texas,
USA, Academic Medical Center, University of
Amsterdam, Netherlands and University of
California, Los Angeles, California, USA). This
study was approved by local institutional review boards for medical record chart review.
Patient selection
Academic Medical Center, University of
Amsterdam, Netherlands: 27 patients, treated
between 1999 and 2012 were identified from a
prospective database (MT=24, IST alone=3).
All patients had an assumed poor prognosis
because of altered mental status or coma,
straight sinus thrombosis, or large space-occupying lesions, such as edema or (hemorrhagic)
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infarcts. Twenty patients have been previously
described 6.
University of Texas Medical Center, Dallas
Texas, USA: 33 patients were identified retrospectively from hospital databases between
1995 and 2012 (MT=7, IST alone=26). Twentythree cases were previously published 24,29-31.
The decision to perform endovascular intervention was operator-dependent.
University of California, Los Angeles, California, USA: three patients were identified retrospectively from hospital databases from 1999
to 2012 (MT=3). Two cases were previously
published 20. The decision to perform endovascular intervention was operator-dependent.
Diagnosis
The diagnosis of CVT was confirmed by
MRI and MR venography, CT venography, or
conventional angiography. The pretreatment
CT or MRI scans were assessed for midline
shift and lesion size, measured as the surface on
the image with the largest diameter of the lesion on the last available scan before thrombolysis. Any cerebral lesion with CT or MRI
signals compatible with blood was defined as
hemorrhagic infarct.

Table 2 Description of mechanical thrombectomy devices and thrombolytic agents.

Variables

Intrasinus thrombolysis
(n=29)

Type of device
AngioJet
Penumbra
	MERCI with Penumbra
	Balloon angioplasty

28
3
1
2

Type of thrombolytics
	Urokinase
tPA
Tirofiban
	None

23
4
2
7

23
6
0
N/A

Continuous thrombolysis

25

29

	Urokinase
tPA
Tirofiban

80,000-100000/h
1 mg/h
0.5 mcg/kg/h
(In conjunction with tPA)

80000-100000/h
1 mg/h
N/A

Duration of continuous thrombolysis

6-96 h

8-96h

N/A=Not applicable
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Mechanical thrombectomy
with/without continuous
thrombolytic infusion
(n=34)

N/A
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Endovascular methods: IST was performed
by introducing a catheter via the internal jugular or femoral vein and advancing it into a
frontal position in the superior sagittal sinus
while the thrombus was dissolved with thrombolytic boluses [urokinase or tissue plasminogen activator (tPA)]. Other sinuses were approached if needed and boluses were given. In
most cases, the catheter was left in situ, and
thrombolytics were infused locally for variable
periods of time depending upon the rate of recanalization. Sinus recanalization was examined by contrast injection through the thrombolysis catheter or by intra-arterial angiography. Recanalization was rated as no recanalization or technical failure, partial or incomplete recanalization (contrast visible but lumen
too narrow) and complete or near complete
recanalization. Heparin was continued during
thrombolytic therapy. In patients who received
MT, thrombosuction/thrombectomy was performed using AngioJet, Penumbra system or
MERCI clot retrieval device.

Outcome variables: Primary outcome variables were discharge mortality and neurological
dysfunction, and intermediate (three months)
and long term (>six months) morbidity utilizing modified Rankin scores (mRS) [(0=complete recovery; 6=death)]. mRS ≤1 was considered a good recovery. Neurological dysfunction
was assessed on admission and discharge and
was rated as neuroscore: 0, normal; 1, mild (ambulatory and communicative); 2, moderate
(non-ambulatory but communicative); 3, severe
(non-ambulatory and non-communicative/
comatose). This scale was previously described
by Wasay et al. in a similar population 29. The
reason for using a non-standardized simple
scale instead of a detailed disability scale is to
minimize the variability in outcome assessment
from chart review 30. Secondary outcome variables included periprocedural complications
(defined as complications within a month of
procedure), recanalization, delayed complications and recurrence rates. Recurrence was defined as clinical (new symptoms or recurrence

Table 3 Comparison of primary outcome variables between MT±IST versus IST alone.

Variables

Death (%)

Mechanical thrombectomy
with/without continuous
thrombolytic infusion
(n=34)

Intrasinus
thrombolysis
(n=29)

p1
(unadjusted)

p2
(adjusted)

7 (21%)

4 (14%)

0.526

0.248†

0.002*

0.442‡

0.060

0.336‡

0.378

0.988‡

Discharge
neurological deficit
	Normal (%)

6 (22%)

17 (68%)

	Mild (%)

13 (48%)

6 (24%)

	Moderate (%)

7 (26%)

2 (8%)

	Severe (%)

1 (4%)

0 (0%)

mRS (3 months)
	Lost to follow-up

2

8

mRS≤1 (%)

17 (68%)

16 (94%)

mRS>1(%)

8 (32%)

1 (6%)

mRS(>6 months)
	Lost to follow-up

5

13

mRS≤1(%)

16 (73%)

11 (92%)

mRS>1(%)

6 (27%)

1 (8%)

mRS=Modified Rankin score; Neuroscore-D=Discharge neuroscore
p1: *p-value represents Wilcoxon-rank sum test and rest of p-values are from Fisher’s exact test
p2: p-values adjusting for neuroscore at admission
† p-value is from Cox regression adjusting for neuroscore at admission
‡ p-value is from logistic regression adjusting for neuroscore at admission
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Figure 1 Kaplan Meyer curve depicting survival rates between MT±IST versus IST alone at discharge.

of previous symptoms) and neuroimaging
(MRI/MRV) evidence of recurrent or more extensive CVT.
Statistical analysis
We used Fisher’s exact test to compare the
categorical variables and Wilcoxon rank sum
test to compare continuous or ordinal variables
between two groups of MT±IST and IST alone.
Log-rank test was performed to determine if
there was a significant difference in patient survival between the two groups. Cox regression
analysis was used to investigate if time was significantly different between the two groups after controlling the effect of admission neuroscore. Logistic regression analysis was conducted to examine if there were significant differences in discharge neurological deficit, dichotomized mRS score (mRS≤1 vs. mRS>1) at three
months and >six months between two groups
after controlling the effect of admission neuroscore. Statistical analyses were two-tailed and
considered significant if p<0.05.
Results
Sixty-three patients underwent endovascular
treatment for CVT. Thirty-four patients received MT +/– IST and 29 patient received IST
alone. Table 1 provides a comparison of demographic and clinical characteristics between patients who received MT +/– IST versus IST
alone. The most common presenting symptom
was headache in both groups. Patients who received MT +/– IST had a higher percentage of
seizures, focal neurological deficits, encephalopathy or coma. They also had significantly
higher admission neuroscores. The reason for
340

an endovascular procedure was well-defined in
patients who received MT +/– IST and included extensive involvement of the sinuses with
altered mental status or coma, deterioration of
symptoms despite being on anticoagulation,
and large space-occupying lesions, such as edema or (hemorrhagic) infarcts. In patients who
received IST only, reasons were less defined
and operator-dependent (Table 1).
The term anticoagulation failure was loosely
used for all patients that deteriorated clinically
on an adequate dose of heparin or oral anticoagulants. The timing of anticoagulation prior to
the procedure was variable and ranged from no
anticoagulation to nine days. Exceptions were
two patients who had a relapse of their symptoms after three months of adequate anticoagulation therapy and were considered candidates for endovascular intervention.
Five patients received heparin only for a few
hours before endovascular intervention mainly
during transfer from a peripheral facility to a
tertiary care center. Eleven patients received
heparin for the first time in the angiography
suite. Twenty patients had no documentation of
prior use of anticoagulation before the procedure.
Mechanical thrombectomy with/without
intrasinus thrombolysis
AngioJet was the most commonly used MT
device (28 patients), followed by Penumbra
and MERCI. Two patients received angioplasty
only. Twenty-seven patients received IST during the procedures. Twenty-five patients received continuous thrombolytic infusion. Urokinase was the most commonly used thrombolytic agent followed by tPA. Duration of thrombolysis varied from six to 96 hours (Table 2).
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Two patients received Tirofiban (Aggrastat,
Medicure Pharma) infusion in conjunction with
tPA. Tirofiban is a glycoprotein IIb/IIIa inhibitor that has been anecdotally used in ischemic
stroke mechanical interventions to maintain
blood flow through channels opened by mechanical thrombectomy especially in the setting
of hypercoagulable states 30,32,33.
Intrasinus thrombolysis: All patients in the
thrombolysis group received continuous infusion for variable duration (8-96 h). The most
commonly used thrombolytic agent was urokinase followed by tPA (Table 2).
Outcome: There was no statistically significant difference in adjusted discharge mortality
between the two groups (7(21%) versus
4(14%), p=0.248) [Table 3, Figure 1]. The unadjusted discharge neuroscore was significantly
higher in patients who received MT (p=0.002).

However, when adjusted for admission neuroscore using a logistic regression model, the difference was not significant (p=0.442).
There was no statistically significant difference in the adjusted intermediate and longterm morbidity between two groups (Table 3).
Periprocedural complications
There was a higher percentage of periprocedural complications in patients who received
MT+/–IST (not significant, P=0.299) (Table 4).
There were five new hemorrhagic infarctions
and three enlargements of prior hemorrhages
in the MT +/– IST group compared to four new
hemorrhagic infarctions in the IST group. Complications secondary to direct catheter manipulations were more prevalent in the MT +/– IST
group (Table 4).

Table 4 Comparison of secondary outcome variables between MT±IST versus IST alone.

Variables

Mechanical thrombectomy Intrasinus thrombolysis
N=29
with/without continuous
thrombolytic infusion
N=34

Hospital stay (median, range)

11 (1-53)

9 (2-30)

0.923

Peri-procedural complications

14(41)

8(28)

0.299

(%)

7

4

Death

5

4

	New ICH

3

0

0

1

Retroperitoneal hemorrhage

1

0

Catheter tip fracture

1

0

Perforation of sinus

1

0

1

0

Recanalization rates

(n=33)

(n=10)‡

	None*(%)

4(12)

0(0)

13(33)

5(50)

	Near to full Improvement†(%)

16(50)

5(50)

Recurrence (%)

1(3)

3(10)

	Worsening of previous ICH
Catheter-related complications

	Groin hematoma
Formation of bilateral inguinal
aneurysm

Partial (%)

0.690

0.286

* One angioplasty and two AngioJet cases
† All Penumbra/MERCI cases
‡ The 19 missing patients had either partial or complete recanalization but not well-documented
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Recanalization rates: Recanalization rates
were available in 33 MT +/– IST patients and
ten IST alone patients. There was no significant
difference between the two groups (Table 4).
Recurrence: The recurrence rate of CVT was
10% (n=3) in the IST alone group and 3%
(n=1) in the MT +/– IST group (p=0.293). Three
patients with recurrence presented within three
months of discharge while one patient presented after two and a half years.
Delayed complications: Three patients in the
MT +/– IST group developed pseudotumor
cerebri with two of them requiring ventriculoperitoneal shunts. All three had either partial
or no recanalization after the procedure. In
three patients from the IST alone group, IST
was performed to treat pseudotumor cerebri
but they continued to have persistent headaches and high intracranial pressure at longterm follow-up.
One patient developed seizures requiring
medications. All four patients had adequate recanalization after the procedure.
Discussion
The first use of IST was reported by Scott et
al. in 1988. They catheterized the sagittal sinus
via a frontal burr hole and infused urokinase
over an eight-hour period, followed by excellent recovery 34.
Dowd et al. reported the first case of using
an MT device to treat CVT. They applied an
AngioJet rheolytic system for thrombectomy
followed by intrasinus infusion of urokinase for
two days. Since then several case reports and
series have been published on the successful
use of either an MT device alone or in combination with direct intrasinus infusion of thrombolytic agents 8.
According to the American Heart Association guidelines for diagnosis and management
of CVT, the use of such procedures is recommended only if clinical deterioration occurs despite use of anticoagulation, or if the patient
develops mass effect from a venous infarction
or ICH that causes intracranial hypertension
resistant to standard therapies 1. However, there
is no proper definition or time limit for anticoagulation failure, as evident from the findings
of our study. Hence, there is variability in the
timing to intervene in patients who are already
on therapeutic anticoagulation. In a recently
published study, Mohammadian et al. defined
342
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anticoagulation failure as clinical deterioration
after at least four days of full anticoagulation
with heparin (or 48 hours in patients with involvement of more than one sinus) 7.
There is only one non-randomized comparison between heparin treatment and IST for the
treatment of CVT. Its findings showed that IST
may offer some benefit over heparin treatment
although the study had several limitations 30. A
clinical trial to compare endovascular treatment (all modalities) versus heparin has been
set-up and is currently recruiting patients 35.
Our study offers a non-randomized comparison between MT +/– IST versus IST alone. The
use of MT versus IST is institute and operatordependent. In our study there was a significant
difference in the choice of treatment between
European and USA institutes. The cases received from the Academic Hospital of Amsterdam, Netherlands primarily used MT in most
patients (24/27), whereas very few cases of attempted MT were found in the UTSW and
UCLA institutional archives. Though theoretically, MT appears to be a better option than
IST alone, clinical data are lacking to support
this hypothesis. Soleu et al., in a small retrospective series of 31 patients who received all
three treatment options (heparin versus IST
versus MT), found MT to be more beneficial
than IST with less hemorrhage risk.
They did not use IST in conjunction with MT
36. Proponents of both treatment modalities
have published case series to advocate local
thrombolysis or mechanical thrombectomy as
safe first or second line treatment options for
severe CVT 7,10. Many interventionalists fear
that the procedure-related complications with
MT devices may cause more harm than benefit
to the patient. Older devices like AngioJet are
bulky and stiff and had potential to cause sinus
perforation. The large size of the AngioJet prevents it from accessing smaller sinuses minimizing its utility. This fear has been overcome in
the recent years with the advent of newer techniques and devices such as Penumbra and
MERCI.
Our study also indicates that in most institutes, MT is reserved mostly for complicated
cases with severe neurological deficits. In milder cases IST is preferred.
Our study offers a modest comparison between two endovascular treatment groups in a
diverse population. When adjusted for injury
severity at admission, both groups had similar
discharge, intermediate and long-term mortali-
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ty and morbidity. Though periprocedural complications and recanalization rates were not significantly different between the two groups, direct catheter-related complications were more
common in the MT group probably secondary
to the more excessive manipulations required
with thrombectomy or thromboaspiration.
Our study has several limitations. It is a retrospective study with non-randomized treatment groups. There is a hospital/operator preference for the treatment modality. The number
of patients is relatively small, although larger
than any previously published series on MT.
We used a simplified scale to monitor outcome
at discharge which is non-standardized. A large
number of patients are lost to follow-up for
long-term evaluations. There is variability of
devices, thrombolytic agents, and the duration
of continuous thrombolytic infusion.

Conclusion
Our study compared two endovascular modalities for the treatment of severe CVT. Both
treatment options have similar discharge, intermediate and long-term mortality and morbidity. However, device-related complications were
more prevalent in the MT group. Based on our
data, the decision to use endovascular options
for the treatment of CVT is operator and institute-dependent. The term ‘anticoagulation failure’ is vague and causes unnecessary confusion
in decision-making. There is a preference to use
IST alone in milder cases of CVT and MT +/IST in severe cases, probably caused by fear of
complications with MT devices. Newer devices
like Penumbra and MERCI have better safety
profiles but data on their application for CVT
is limited.
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